Scholar Rock’s Rise: A Spark in the Biotech Horizon
In the stillness before the market’s hum, an analyst from Leerink Partners, Mani Foroohar, gave his blessing to Scholar Rock, assigning it a rating of “outperform”-a subtle yet potent invitation to embrace the stock with eager arms. His target price: $51 per share, a number with a promise nearly 51% greater than Scholar Rock’s last closing price. For a company just beginning to cast its shadow, such growth seems almost inevitable. What is a stock’s rise but the shadow of a company’s soul reaching across the landscape, stirring the winds of fortune?